Corcept Therapeutics’ (NASDAQ:CORT) stock dropped by about 50% after the FDA demanded additional data supporting the efficacy relacorilant for Cushing syndrome, the company’s candidate treatment.
Analysts reassessed CORT after the setback. This shows how sensitive the market is to changes in regulatory policies for small-cap pharmaceutical companies.
Corcept’s stock has fallen 70% since its high of late March.
Corcept Stock: What the FDA Setback Means
Investors’ confidence in Corcept has been materially affected by FDA’s demand for additional evidence about relacorilant.
CORT sells Korlym, which was anticipated to drive revenue in the Cushing syndrome market.
Analysts have accounted for the fact that relacorilant is now subject to delays and possible rejection by removing it from financial models.
Korlym is also under threat from generic competitors, notably Teva Pharmaceuticals. CORT’s stock has limited potential for growth in its core therapeutic areas.
This regulatory obstacle not only affects future sales, but raises concerns about Corcept Therapeutics clinical data strategy and robustness.
CORT’s share price may be overdone
Some analysts think that the reaction of the stock market may have been overblown despite the FDA’s major setback.
Truist Securities has, for instance, reduced its price target on Corcept’s shares from $100 to $50. They acknowledge that recent news was a significant negative for the biotech company.
The investment firm still maintained its “buy” ratings, and the price targets, even though they were revised downward, indicate a potential gain of over 40%.
Analysts at the company noted that “we see value in Korlym for Cushing’s, with potential upside from Relacorilant (in PROC)”, referring to platinum resistant ovarian carcinoma.
Corcept Therapeutics, after today’s crash is aiming for only a P/S ratio of 10 or less, which is not expensive at all for a biotech firm that is growing quickly.
While the FDA’s news was undoubtedly negative, it may not be necessary to remove relacorilant from all valuation models, particularly if management is able to address agency concerns.
Why should you purchase Corcept at a pullback price?
CORT may still be a good investment in 2026 as this is not one of the unprofitable names.
The company reported a net profit of nearly $20 million and a revenue of $208 millions in the last quarter. This is an increase by 14% compared to the previous year.
Corcept has a strong balance sheet, and the ongoing research into ovarian carcinoma could open up new revenue streams.
Korlym continues to produce cash flow despite generic headwinds. Relacorilant’s oncology potential remains unaffected.
Long-term investors may find the current price attractive, particularly if management is able to navigate regulatory hurdles and diversify their pipeline.
Corcept’s fundamentals indicate that it is not broken. The stock may be able to recover in the coming months with clarity and execution.
What happened to Corcept Therapeutics today? This post may be updated as new information unfolds
